• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

After obesity, Pfizer and Flagship pick 2 more targets for multibillion-dollar partnership

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 28, 2024 at 11:42: AM
via Flagship Pioneering and Pfizer have added Quotient into their 10-program partnership, inking a deal to discover new targets for two programs in cardiovascular and renal diseases.

The deal fits into a larger equation: Back in July 2023, Pfizer and Flagship Pioneering each put down $50 million to build a 10-program pipeline.

article source
 

<



Similar threads

cafead
Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity
Replies
0
Views
27
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer’s Bourla confident in company’s obesity drug position, despite delays
Replies
0
Views
27
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer&#039;s obesity pill news leaves analysts wanting, biotech investors cheering
Replies
0
Views
13
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
Replies
0
Views
162
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer plans to be &#039;very active&#039; in obesity market, but CEO mum on precise...
Replies
0
Views
55
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote